NEW YORK (AP) — Shares of drug developer BIND Therapeutics fell in its first day of trading on the Nasdaq.
The stock dropped 91 cents, or 6.1 percent, to close at $14.09 Friday after raising $70.5 million in an initial public offering of stock.
BIND Therapeutics Inc. priced the offering of 4.7 million shares at $15 each, in the middle of the expected range.
BIND Therapeutics has no products on the market. Its most advanced treatment candidate, BIND-014, is in mid-stage clinical development as a possible treatment for a form of lung cancer and an advanced form of prostate cancer. The company plans to use the offering's proceeds in part to fund BIND-014 development.
The Cambridge, Mass., company trades under the "BIND" ticker symbol.
'Scary as hell': Pens featuring Hillary Clinton's cackling head spreading by postal mail
Mexico's Immigration Law: Let's Try It Here at Home | Human Events
Nick Adams - Not a Single Illegal Immigrant in 7 Months... In Australia
John Hawkins - If Trump's Campaign Collapses, It'll Be For One Of These 6 Reasons
DNC trying to insulate itself from Iran disaster. Or maybe just Debbie Wasserman Schultz is. | RedState
Man Dies Attempting Appendix Carry Reholster In Milkwaukee - Bearing Arms - appendix carry, Milwaukee, Negligent Discharge, Timothy Phonisay, Wisconsin
Quotes of the day - Hot Air